Patient focused research for better outcomes
Find out how supporting the patient journey with customised services will increase patient centricity in your clinical trials.
This whitepaper discusses the varying regulatory and legal jurisdictions across countries for decentralised clinical trials, including a summary of the recent FDA draft guidance on the use of digital health technology.Read the whitepaper
The FDA’s new FDORA bill includes provisions intended to improve diversity in trial enrolment through decentralised clinical trials and associated digital health technologies.Read the blog
Everyone is talking about decentralised clinical trials. But how can we leverage what we learnt during 2020 and move forward in a more systematic way to deploy this approach with maximum efficiency and optimum results?Read the whitepaper
ICON invited senior biopharma executives to discuss how decentralised and hybrid clinical trial models can provide increased resilience and to share how their respective organisations are currently or likely to address diversity and inclusion in clinical trials going forward. This summary report outlines how these executives see the opportunity in the developments of 2020, paving the way for continuous improvements into the future.Read the summary report
Engaging patients more fully and making sure decentralised clinical trials are easing rather increasing burden is going to be crucial to using these models in the longer term. Early in 2021, ICON conducted a survey to compare it to one conducted in 2019 to see if the COVID-19 outbreak had changed the sentiment and increased interest in participating in clinical trials remotely.Read the survey results
Although mHealth devices and sensors are continuing to evolve, and it is now possible to capture a vast array of physiological data, the operationalisation of digital trials is not without challenges. Navigate the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.Read the whitepaper
During COVID-19 the levels of remote monitoring increased due to site closures and safety reasons. Now is the time to learn from that experience and review whether a hybrid model of remote monitoring and centralised monitoring is the way forward for some trials. Learn best practices in analysing and assessing risk in clinical monitoring and how to remain agile adapting to environmental conditions and therapeutic focus.Read the whitepaper
Find out how these services are increasing patient recruitment and retention:
Understand how to implement wearable devices and harness digital endpoints in clinical trials:
The Financial Times in partnership with ICON, brought together senior leaders from Biogen, Bayer and AbbVie to discuss their most recent experience of decentralised clinical trials, where they see the issues and share the strategies and tactics they are exploring to deliver success.
Emily Mitchell and Mike Andino discuss the rising demand to address diversity in clinical trials and how decentralising clinical trials and tailoring patient strategies will improve results.
Harpreet Gill and Ashmee Bharadia explore the importance of investigator buy-in to decentralised clinical trials and practical steps to enhance collaboration.
This webinar explores the challenges and concerns of key stakeholders regarding in-home services, and how to overcome them using tried and trusted methods.
This blog examines the crucial topic of regulating the use of DCTs, exploring what’s in place now and what sponsors need to consider as these methods continue to gain traction.
The FDA’s new FDORA bill includes provisions intended to improve diversity in trial enrolment through decentralised clinical trials and associated digital health technologies.
The collection of real-time data in a home setting can give sponsors and trial managers greater visibility and assurance around GCP and protocol compliance.
How to best incorporate digital endpoints at every stage of clinical research.
An end-to-end approach to managing wearable devices through clinical development.
This article in the Journal of mHealth explores the guidance regulators have provided for diversity and inclusion in clinical trials, privacy considerations and endpoint selection.
Ute Berger, President, Development & Commercialisation Solutions outlines how ICON is transforming clinical trials in a rapidly shifting landscape in the Executive Interview in Drug Development & Delivery.
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
As DCT adoption increases, Harpreet Gill looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.
Matt Harrington explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
Emily Mitchell discusses the importance of considering the target patient population when designing and deploying a decentralised clinical trial.
Emily Mitchell and Kathleen Mandziuk discuss how study data has progressed in recent years and how trial teams can keep up effectively with proper data management.
A snapshot from the J.P. Morgan Healthcare Conference 2022.
Emily Mitchell and Christina Dinger run through some of the most important elements of collating and organising data during clinical trials.
This three part video series examines some of the factors that should be considered to ensure that clinical trial data captured via wearable devices, is monitored expeditiously and effectively.
The research industry has changed in the past year, and decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
Digital health has been a hot topic for many years, but it has taken the pandemic to really highlight its value across many areas of the pharma and biotech industries.
Choosing the best option for your clinical trial.
Wearables are improving the clinical trial experience for patients and satisfying the need to collect data for real-world use studies.
Starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
Reducing the burden that clinical trial participation places on patients can help to keep patients engaged in clinical research.
Seven steps to closing the gap between rhetoric and reality in patient-centricity.
Exploring the patient perspective from different angles.
Steps to implement security into mHealth development.
Patient engagement is permeating all spheres of the healthcare ecosystem.
Revolutionising clinical trials with wearables and digital endpoints.
Project teams need to be challenged constantly to justify the study procedures and eligibility criteria they are proposing.
Decentralised and hybrid trials bring a wide range of benefits to the patient and the sponsor. Find out more about the range of decentralised and hybrid trials services available from ICON.Read more about ICON's services